

# Medical Preferred Drug List (Marketplace) – July 2025

## Prepared for Marketplace

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
Acromegaly	Sandostatin® LAR Depot (octreotide acetate) Signifor® LAR (pasireotide) Somavert (pegvisomant) Somatuline Depot® (Lanreotide)	Ianreotide acetate (CIPLA)
Alpha-1 Antitrypsin Deficiency	Aralast® (Alpha-1-Proteinase Inhibitor) Glassia® (Alpha-1-Proteinase Inhibitor)	Prolastin C® (Alpha-1-Proteinase Inhibitor) Zemaira® (Alpha-1-Proteinase Inhibitor)
Antiviral-MAB-RSV	Synagis (palivizumab)	Beyfortus® (nirsevimab-alip)
Autoimmune	Actemra® (tocilizumab) IV Tofidence® (tocilizumab) Tyenne® (tocilizumab) Cimzia® (certolizumab pegol) Orencia®(abatacept) Cosentyx (secukinumab) IV Omvoh® (mirikizumab-mrkz)	Envyio® (vedolizumab) Ilumya™ (tilgrakizumab-asmn) Simoni Aria® (golimumab) Stelara®(ustekinumab) Skyrizi (risankizumab-rzaa) Tremfya® (guselkumab)
Autoimmune – Infliximab/Remicade	Remicade (infliximab) Infliximab (unbranded) Zymfentra (infliximab-dyyb)	Avsola (infliximab-axxq) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)
Botulinum Toxins	Myobloc® (rimabotulinumtoxin B) Dysport® (abobotulinumtoxin A)	Botox® (onabotulinumtoxin A) Xeomin® (incobotulinumtoxin A) Daxxify (daxibotulinumtoxin A-lanm)
*Hematologic, Colony Stimulating Factors – Short Acting	Granix® (tbo-filgrastum) Leukine® (sargramostim) Neupogen® (filgrastim)	Zarxio® (filgrastim-sndz) Nivestym® (filgrastim-aafi) Releuko® (filgrastim-ayow)
*Hematologic, Colony Stimulating Factors – Long Acting	Fylnetra® (pegfilgrastim-pbbk) Nyvepria™(pegfilgrastim-apgf) Rolvedon® (eflapegrastim-xnst) Stimufend®(pegfilgrastim-fpgk) Udenyca® (pegfilgrastim-cbqv) Ziextenzo® (pegfilgrastim-bmez) Ryzneuta (efbemalenograstim-alfa)	Fulphila™ (pegfilgrastim-jmdb) Neulasta® (pegfilgrastim)
Hematologic, Erythropoiesis- Stimulating Agents	Epogen® (epoetin alfa) Mircera® (methoxy polyethylene glycol- epoetin beta)	Aranesp® (darbepoetin) Procrit® (epoetin alfa)

\*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. \*\*Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
	Retacrit® (epoetin alfa-epbx)	
Heme, IV Iron	Feraheme (ferumoxytol) Ferumoxytol (generic) Injectafer (ferric carboxymaltose) Monoferric (ferric derisomaltose)	Ferrlecit (sodium ferric gluconate) Infed (Iron dextran) Venofer (iron sucrose)
Hemophilia, Factor VIII	Helixate® [Antihemophilic Factor (recombinant), Formulated with Sucrose] Recombinate® [Antihemophilic Factor (recombinant)]	Advate® [antihemophilic factor (recombinant)] Afstyla® [antihemophilic factor (recombinant)] Adynovate® [antihemophilic factor (recombinant), PEGylated] Eloctate® (antihemophilic factor recombinant Fc fusion protein) Jivi® [antihemophilic factor (recombinant), PEGylated] Kogenate®[antihemophilic factor (recombinant)] Kovaltry®[antihemophilic factor (recombinant)] Novoeight® [antihemophilic factor (recombinant)] Nuwiq® [antihemophilic Factor (recombinant)] Xyntha® [antihemophilic Factor (recombinant)]
Immune Globulin – IV	Asceniv (immune globulin) Carimune (immune globulin) Gammaplex (immune globulin) Panzyga (immune globulin) Vivaglobin (immune globulin)	Bivigam (immune globulin) Flebogamma (immune globulin) Gammagard (immune globulin) Gammagard S/D (immune globulin) Gamunex-C (immune globulin) Gammaked (immune globulin) Octagam (immune globulin) Privigen (immune globulin)
Long-Acting Reversible Contraceptives		Kyleena® (levonorgestrel-releasing intrauterine system) Mirena® (levonorgestrel-releasing intrauterine system) Skyla® (levonorgestrel-releasing intrauterine system) Liletta® (levonorgestrel-releasing intrauterine system) Nexplanon® (etonogestrel implant) Paragard (intrauterine copper)
Lysosomal Storage Disorders – Gaucher Disease	VPRIV® (velaglucerase alfa)	Cerezyme® (imiglucerase) Elelyso® (taliglucerase alfa)

\*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. \*\*Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.



Drug Class	Non-Preferred Product(s)	Preferred Product(s)
Multiple Sclerosis (Infused)	Lemtrada® (alemtuzumab) Briumvi (ublituximab-xiiy) Ocrevus Zunovo® (ocrelizumab-hyaluronidase) Tyruko (natalizumab)	Tysabri® (natalizumab) Ocrevus® (ocrelizumab)
Myasthenia Gravis/Paroxysmal Nocturnal Hemoglobinuria (PNH)	Empaveli® (pegcetaclopan) Soliris® (eculizumab) Ultomiris® (Ravulizumab-cwrz)	Bkemv®(eculizumab) Epysqli®(eculizumab)
Osteoarthritis, Viscosupplements	Gelsyn-3® (sodium hyaluronate) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis (sodium hyaluronate) Supartz® FX (1% sodium hyaluronate) SynoJoynt® (1% sodium hyaluronate) Synvisc/Synvisc ONE® (hylan (Avian) 8 mg/mL) Triluron® (sodium hyaluronate) TriVisc®(sodium hyaluronate) Visco-3® (1% sodium hyaluronate)	Euflexxa® (1% sodium hyaluronate) Orthovisc® (1% sodium hyaluronate) Monovisc® (sodium hyaluronate)
*Oncology	**Avastin® (bevacizumab) Vegzelma (bevacizumab-adcd)	Mvasi™ (bevacizumab-awwb) Zirabev® (bevacizumab-bvzr) Alymsys (bevacizumab-maly)
	Herceptin® (trastuzumab) Herceptin Hycelta™ (trastuzumab and hyaluronidase-oysk) Hercessi (trastuzumab-strf) Herzuma® (trastuzumab-pkrb) Ogivri™ (trastuzumab-dkst) Ontruzant® (trastuzumab-dttb)	Kanjinti™(trastuzumab-anns) Trazimera™ (trastuzumab-qyyp)
*Rituximab	Rituxan® (rituximab) Rituxan Hycela®(rituximab-hyaluronidase) Truxima®(rituximab-abbs)	Ruxience®(rituximab-pvvr) Riabni™ (rituximab-arrx)
Retinal Disorders (Eye)	Eylea®(aflibercept) Pavblu®(aflibercept) Enzeevu®(aflibercept) Ahzantive®(aflibercept) Opuviz®(aflibercept) Beovu® (brolucizumab-dblI) Macugen (pegaptanib) Susvimo™ (ranibizumab) Lucentis®(ranibizumab) Byooviz®(ranibizumab) Cimerli® (ranibizumab-eqrn) Vabysmo™ (faricimab-svoa) Visudyne® (verteporfin)	**Avastin® (bevacizumab)

\*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. \*\*Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

